Polymorphism of Transporter Genes Contributes to Variations in Treatment Outcomes and Adverse Events in Platinum Based- Chemotherapy- Treated Oral Cancer Patients

References

• Wong TSC, Wiesenfeld D. Oral cancer. Aust Dent J. 2018;63(S1):S91–11. doi:10.1111/adj.12594.
   PubMedGoogle Scholar
• Gupta B, Bray F, Kumar N, Johnson NW. Associations between oral hygiene habits, diet, tobacco and alcohol and risk of oral cancer: a case–control study from India. Cancer Epidemiol. 2017;51:7–14. doi:10.1016/J.CANEP.2017.09.003.
   PubMed Web of Science ®Google Scholar
• Veluthattil A, Sudha S, Kandasamy S, Chakkalakkoombil S. Effect of hypofractionated, palliative radiotherapy on quality of life in late-stage oral cavity cancer: a prospective clinical trial. Indian J Palliat Care. 2019;25(3):383–90. doi:10.4103/IJPC.IJPC_115_18.
   PubMed Web of Science ®Google Scholar
• Li CC, Shen Z, Bavarian R, Yang F, Bhattacharya A. Oral cancer: genetics and the role of precision medicine. Dent Clin North Am. 2018;62(1):29–46. doi:10.1016/J.CDEN.2017.08.002.
   PubMedGoogle Scholar
• Mustian KM, Devine K, Ryan JLJanelsins M.C, Sprod L.K, Peppone L.J, Candelario G.D, Mohile S.G, Morrow G.R. Treatment of nausea and vomiting during chemotherapy. US Oncol Hematol. 2011;7(2):91. doi:10.17925/OHR.2011.07.2.91.
   PubMedGoogle Scholar
• Zhong LP, Zhang CP, Ren GX, Guo W, William WN, Sun J, Zhu H-G, Tu W-Y, Li J, Cai Y-L, et al. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol. 2013;31(6):744–51. doi:10.1200/JCO.2012.43.8820.
   PubMed Web of Science ®Google Scholar
• Pêtre A, Dalban C, Karabajakian A, Neidhardt EM, Roux PE, Poupart M, Deneuve S, Zrounba P, Fayette J. Carboplatin in combination with weekly paclitaxel as first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma unfit to EXTREME schedule. Oncotarget. 2018;9(31):22038. doi:10.18632/ONCOTARGET.25157.
   PubMedGoogle Scholar
• Cao S, Wang C, Ma H, Yin R, Zhu M, Shen W, Dai J, Shu Y, Xu L, Hu Z, et al. Genome-wide association study on platinum-induced hepatotoxicity in non-small cell lung cancer patients. Sci Rep. 2015;5(1):5. doi:10.1038/SREP11556.
   Google Scholar
• Xiong Y, Huang BY, Yin JY. Pharmacogenomics of platinum-based chemotherapy in non-small cell lung cancer: focusing on DNA repair systems. Med Oncol. 2017;34(4). doi:10.1007/S12032-017-0905-6.
   PubMed Web of Science ®Google Scholar
• Islam MS, Islam MS, Parvin S, Ahmed MU, Sayeed MSB, Uddin MMN, Hussain SMA, Hasnat A. Effect of GSTP1 and ABCC4 gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-5-fluorouracil-based chemotherapy in Bangladeshi breast cancer patients. Tumor Biol. 2015;36(7):5451–57. doi:10.1007/S13277-015-3211-Y.
   PubMedGoogle Scholar
• Hampras SS, Sucheston L, Weiss J, Baer MR, Zirpoli G, Singh PK, Wetzler M, Chennamaneni R, Blanco JG, Ford L, et al. Genetic polymorphisms of ATP-binding cassette (ABC) proteins, overall survival and drug toxicity in patients with acute myeloid leukemi. Int J Mol Epidemiol Genet. 2010;1(3):201–07. [accessed 2023 May 28]. https://pubmed.ncbi.nlm.nih.gov/21311724/.
   PubMedGoogle Scholar
• Kato H, Sassa N, Miyazaki M, Takeuchi M, Asai M, Iwai A, Noda Y, Gotoh M, Yamada K. Association of axitinib plasma exposure and genetic polymorphisms of ABC transporters with axitinib-induced toxicities in patients with renal cell carcinoma. Cancer Chemother Pharmacol. 2016;78(4):855–62. doi:10.1007/S00280-016-3145-0.
   PubMed Web of Science ®Google Scholar
• De Mattia E, Toffoli G, Polesel J, D’Andrea M, Corona G, Zagonel V, Buonadonna A, Dreussi E, Cecchin E. Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment. Pharmacogenet Genomics. 2013;23(10):549–57. doi:10.1097/FPC.0B013E328364B6CF.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. doi:10.1016/J.EJCA.2008.10.026.
   PubMed Web of Science ®Google Scholar
• Molecular cloning: a laboratory manual. In: Sambrook JF, and Russell DW, editors. Includes bibliographical references and index. 3rd ed., Vol. 1–3. Cold Spring Harbor Laboratory Press; 2001. p. 2100. Soft cover | sigma-aldrich. [accessed 2023 Feb 7].https://www.sigmaaldrich.com/IN/en/product/sigma/m8265?gclid=Cj0KCQiA54KfBhCKARIsAJzSrdp8ZOYtqvt85MyqjIXVvHzdhprJfxsG_fYaly5DRls4vsEyxMOZi9AaAqjXEALw_wcB&gclsrc=aw.ds.
   Google Scholar
• Kiyotani K, Mushiroda T, Kubo M, Zembutsu H, Sugiyama Y, Nakamura Y. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci. 2008;99(5):967–72. doi:10.1111/J.1349-7006.2008.00765.X.
   PubMed Web of Science ®Google Scholar
• Choi JR, Kim JO, Kang DR, Shin J-Y, Zhang XH, Oh JE, Park J-Y, Kim K-A, Kang J-H. Genetic variations of drug transporters can influence on drug response in patients treated with docetaxel chemotherapy. Cancer Res Treat. 2015;47(3):509–17. doi:10.4143/CRT.2014.012.
   PubMed Web of Science ®Google Scholar
• Chew SC, Singh O, Chen X, Ramasamy RD, Kulkarni T, Lee EJD, Tan E-H, Lim W-T, Chowbay B. The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients. Cancer Chemother Pharmacol. 2011;67(6):1471–78. doi:10.1007/S00280-011-1625-9.
   PubMed Web of Science ®Google Scholar
• Sharma P, Singh N, Sharma S. Genetic variations in ABC transporter genes as a predictive biomarker for toxicity in North Indian lung cancer patients undergoing platinum-based doublet chemotherapy. J Biochem Mol Toxicol. 2023;37(3). doi:10.1002/JBT.23269.
   Web of Science ®Google Scholar
• Wang L, Sun C, Li X, Mao C, Qian J, Wang J, Wu J, Li Q, Bai C, Han B, et al. A pharmacogenetics study of platinum-based chemotherapy in lung cancer: ABCG2 polymorphism and its genetic interaction with SLC31A1 are associated with response and survival. J Cancer. 2021;12(5):1270–83. doi:10.7150/JCA.51621.
   PubMed Web of Science ®Google Scholar
• Han JY, Lim HS, Yoo YK, Shin ES, Park YH, Lee SY, Lee J-E, Lee DH, Kim HT, Lee JS, et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer. 2007;110(1):138–47. doi:10.1002/CNCR.22760.
   PubMed Web of Science ®Google Scholar
• De Jong FA, Scott-Horton TJ, Kroetz DL, McLeod HL, Friberg LE, Mathijssen RH, Verweij J, Marsh S, Sparreboom A. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther. 2007;81(1):42–49. doi:10.1038/SJ.CLPT.6100019.
   PubMed Web of Science ®Google Scholar
• Han JY, Lim HS, Park YH, Lee SY, Lee JS. Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer. 2009;63(1):115–20. doi:10.1016/J.LUNGCAN.2007.12.003.
   PubMed Web of Science ®Google Scholar
• Borst P, De Wolf C, Van De Wetering K. Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch. 2007;453(5):661–73. doi:10.1007/S00424-006-0054-9.
   PubMed Web of Science ®Google Scholar
• Zhao X, Guo Y, Yue W, Zhang L, Gu M, Wang Y. ABCC4 is required for cell proliferation and tumorigenesis in non-small cell lung cancer. Oncotargets Ther. 2014;7:343–51. doi:10.2147/OTT.S56029.
   PubMed Web of Science ®Google Scholar
• Van Aubel RAMH, Smeets PHE, Van Den Heuvel JJMW, Russel FGM. Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am J Physiol Renal. 2005;288(2):F327–33. doi:10.1152/AJPRENAL.00133.2004.
   PubMed Web of Science ®Google Scholar
• Low SK, Kiyotani K, Mushiroda T, Daigo Y, Nakamura Y, Zembutsu H. Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients. J Hum Genet. 2009;54(10):564–71. doi:10.1038/JHG.2009.79.
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP–dependent transporters. Nat Rev Cancer. 2002;2(1):48–58. doi:10.1038/NRC706.
   PubMed Web of Science ®Google Scholar
• Theile D, Grebhardt S, Haefeli WE, Weiss J. Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy. Biochem Pharmacol. 2009;78(11):1366–73. doi:10.1016/J.BCP.2009.07.006.
   PubMed Web of Science ®Google Scholar
• Cecchin E, D’Andrea M, Lonardi S, Zanusso C, Pella N, Errante D, De Mattia E, Polesel J, Innocenti F, Toffoli G, et al. A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. Pharmacogenomics J. 2013;13(5):403–09. doi:10.1038/TPJ.2012.31.
   PubMed Web of Science ®Google Scholar
• Vulsteke C, Lambrechts D, Dieudonné A, Hatse S, Brouwers B, van Brussel T, Neven P, Belmans A, Schöffski P, Paridaens R, et al. Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). Ann Oncol. 2013;24(6):1513–25. doi:10.1093/ANNONC/MDT008.
   PubMed Web of Science ®Google Scholar
• Schreurs WHP, Odink J, Egger RJ, Wedel M, Bruning PF. The influence of radiotherapy and chemotherapy on the vitamin status of cancer patients. Int J Vitamin Nutr Res. 1985; 55(4):425–32. [accessed 2023 May 28]. https://pubmed.ncbi.nlm.nih.gov/4086213/.
   PubMed Web of Science ®Google Scholar